Funding for this research was provided by:
Horizon 2020 Framework Programme (634570)
H2020 European Research Council (742432)
The Eve Appeal
Received: 29 July 2020
Accepted: 3 November 2020
First Online: 23 November 2020
Ethics approval and consent to participate
: The study itself is a sub-study of the FORECEE (4C) Program, which has ethical approval from the UK Health Research Authority (REC 14/LO/1633). All participants provided written informed consent [CitationRef removed].
: AL and TP are employees of Eurofins, which offers 16S rRNA gene sequencing as a service. NC reports personal fees from Roche, Pharmamar, AstraZeneca, Clovis, Tesaro, Pfizer, Takeda and Biocad. All other authors declare no competing interests.